Last update 08 May 2025

IGF-1R x ALK x INSR x ROS1

Basic Info

Related Targets
IGF-1RALKINSR[+1]

Related

1
Drugs associated with IGF-1R x ALK x INSR x ROS1
Ceritinib
Target
ALK x IGF-1R x INSR x ROS1
Mechanism
ALK inhibitors [+3]
Active Org.
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp. [+4]
Originator Org.
Novartis Pharma AG
Active Indication
Non-Small Cell Lung Cancer [+2]
Inactive Indication
Adenocarcinoma of Esophagus [+24]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date29 Apr 2014
61
Clinical Trials associated with IGF-1R x ALK x INSR x ROS1
NCT06813079
/ Not yet recruitingPhase 2IIT
ADOPT: Adaptive Organoid-Based Precision Therapy Study in Pancreatic Cancer - A Prospective Single-Arm Phase II Trial
100 Clinical Results associated with IGF-1R x ALK x INSR x ROS1
Login to view more data
100 Translational Medicine associated with IGF-1R x ALK x INSR x ROS1
Login to view more data
0 Patents (Medical) associated with IGF-1R x ALK x INSR x ROS1
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free